GPR55 and colitis: The GPR55 antagonist CID16020046 and GPR55-/- mice exhibit less severe colitis in response to DSS or TNBS, contrary to genetic knockout or pharmacological inhibition of CB1/2.101 Therefore, whereas CB1/2 are likely to have anti-inflammatory effects, GPR55 triggers a pro-inflammatory cascade.